Press Releases

STOCKHOLM, May 3, 2024 /PRNewswire/ -- Ericsson's (NASDAQ: ERIC) annual general meeting on April 3, 2024 authorized the company to, in conjunction with the delivery of vested shares under the long-term variable compensation program 2021 ("LTV 2021"), prior to the annual general meeting in 2025, retain and sell no more than 60% of the vested LTV 2021 shares of series B in the company in order to cover for the costs for withholding and paying tax and social security... (continue reading...)

DENVER--(BUSINESS WIRE)-- AngloGold Ashanti plc (“AGA”) will release its Q1 2024 Production Update on 10 May 2024. We invite you to participate in our Market call via webcast or conference call.

Market Call 10 May 2024 09:00 ET / 14:00 UK / 15:00 CAT

Conference call pre-registration: https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=6868254&linkSecurityString=175bcfb2c2

Webcast link: ... (continue reading...)

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 3 MAY 2024 10.15 A.M. EET, MANAGER’S TRANSACTION

Oma Savings Bank Plc: Manager´s Transactions – Aila Hemminki

Person subject to the notification requirements:

Name: Aila HemminkiPosition: Member of the Board/Deputy Member

Issuer: Oma Savings Bank PlcLEI: 743700LE1ECAPXC5UT18Notification type: INITIAL NOTIFICATIONReference number: 61186/5/10____________________________________________

Transaction date:... (continue reading...)

Q1 2024 Trading Update (Unaudited)

COPENHAGEN--(BUSINESS WIRE)-- In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage asset to LEO Pharma’s medical dermatology pipeline, and delgocitinib for chronic hand eczema (CHE) is on track for its planned European launch in Q4... (continue reading...)

MILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of the clinical trial design of the Company’s lead program in Usher 1B by the program’s Principal Investigator, Prof. Francesca Simonelli, at the 9th Annual Retinal Cell and Gene Therapy Innovation... (continue reading...)